Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00543231 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of G3139 Subcutaneous in Solid Tumors
A Phase 1 study, sponsored by Genta Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00543231: Completed Phase 1 study, sponsored by Genta Incorporated.
NCT00543231 is a Phase 1 study that has completed, run by Genta Incorporated. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00543231, a Phase 1 study, has completed, sponsored by Genta Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Genasense® is currently administered to subjects in clinical studies as a multiple-day continuous intravenous infusion. Subjects are treated on an outpatient basis and carry a pump that delivers the drug through a peripheral or central intravenous line. The route of administration limits the convenience of treatment, and catheter-related complications have been reported. This study is designed to evaluate the pharmacokinetics and safety of G3139 administered by subcutaneuous injection.
Interventions
- DRUG G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2005-12 |
| Est. Completion | 2006-12 |
| Phase | Phase 1 |
What the finished NCT00543231 record still lists
NCT00543231 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide is the first listed.
NCT00543231 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00543231 about?
NCT00543231 is a clinical study titled "A Phase I Study of G3139 Subcutaneous in Solid Tumors". Genasense® is currently administered to subjects in clinical studies as a multiple-day continuous intravenous infusion. Subjects are treated on an outpatient basis and carry a pump that delivers the drug through a peripheral or central intravenous line. The route of administration limits the conveni...
What is the current status of trial NCT00543231?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2005-12. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00543231?
The interventions under investigation include: G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide (DRUG).
Who is sponsoring clinical trial NCT00543231?
This trial is sponsored by Genta Incorporated, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00543231's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia